Sumitomo Life Insurance Co. Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sumitomo Life Insurance Co. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,112 shares of the biopharmaceutical company’s stock after selling 62 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in Regeneron Pharmaceuticals were worth $2,217,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. R Squared Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $435,000. SteelPeak Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 154.8% in the 4th quarter. SteelPeak Wealth LLC now owns 2,823 shares of the biopharmaceutical company’s stock worth $2,011,000 after buying an additional 1,715 shares during the last quarter. Tamar Securities LLC raised its position in Regeneron Pharmaceuticals by 31.7% during the fourth quarter. Tamar Securities LLC now owns 20,401 shares of the biopharmaceutical company’s stock valued at $14,532,000 after purchasing an additional 4,909 shares in the last quarter. Nilsine Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 2.8% during the 4th quarter. Nilsine Partners LLC now owns 1,006 shares of the biopharmaceutical company’s stock valued at $717,000 after buying an additional 27 shares in the last quarter. Finally, Slow Capital Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Slow Capital Inc. now owns 12,765 shares of the biopharmaceutical company’s stock worth $9,093,000 after acquiring an additional 410 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on REGN. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Citigroup reduced their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $686.33 on Wednesday. The stock has a market cap of $75.42 billion, a price-to-earnings ratio of 16.98, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm has a 50-day moving average of $725.65 and a two-hundred day moving average of $933.22. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.